Chiltern, Charles River Labs Partner on Early-phase Studies

Friday, February 26, 2010 06:54 AM

UK contract research organization (CRO) Chiltern International and preclinical CRO Charles River Laboratories are partnering to conduct and support early-phase radiolabelled studies.

The two companies will collaborate on studies using radiolabelled investigational products out of the CROs’ Europe-based facilities.

Chiltern’s early stage division—Chiltern Early Phase—in Dundee, Scotland, will perform the clinical aspects of the studies. The CRO has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Charles River’s Metabolism and Pharmacokinetics facilty in Edinburgh includes a GMP clean room, licensed for the manufacture of radiolabelled drug products. The close proximity of the two laboratories enables the companies to turn around radioactivity data within 24 hours.

“This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC,” said Chiltern CEO Glenn Kerkhof in a statement. “These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs